Apotex Inc., a Canada-based global health company, announced on Wednesday that Health Canada has approved Aflivu (aflibercept), a biosimilar to Eylea, indicated for the treatment of neovascular (wet) age-related macular degeneration, macular oedema secondary to central or branch retinal vein occlusion, treatment of diabetic macular oedema, and treatment of myopic choroidal neovascularisation.

Apotex says that this approval marks a key milestone for the company, introducing its first ophthalmic biosimilar and its fourth biosimilar since 2016, and reflecting the company's commitment to expand its biologics portfolio and execution of its Journey of Health strategy.

Aflivu joins Apotex's existing biosimilar portfolio, which includes Grastofil (filgrastim), Lapelga (pegfilgrastim), and Bambevi (bevacizumab).